SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediator

Lisiena Hysenaj,Samantha Little,Kayla Kulhanek,Oghenekevwe M. Gbenedio,Lauren Rodriguez,Alan Shen,Jean-Christophe Lone,Leonard C. Lupin-Jimenez,Luke R. Bonser,Nina K. Serwas,Kriti Bahl,Eran Mick,Jack Z. Li,Vivianne W. Ding,Shotaro Matsumoto,Mazharul Maishan,Camille Simoneau,Gabriela Fragiadakis,David M. Jablons,Charles R. Langelier,Michael Matthay,Melanie Ott,Matthew Krummel,Alexis J. Combes,Anita Sil,David J. Erle,Johannes R. Kratz,Jeroen P. Roose
DOI: https://doi.org/10.1101/2021.06.01.446640
2021-06-02
Abstract:Abstract SARS coronavirus-2 (SARS-CoV-2) is causing a global pandemic with large variation in COVID-19 disease spectrum. SARS-CoV-2 infection requires host receptor ACE2 on lung epithelium, but epithelial underpinnings of variation are largely unknown. We capitalized on comprehensive organoid assays to report remarkable variation in SARS-CoV-2 infection rates of lung organoids from different subjects. Tropism is highest for TUBA- and MUC5AC-positive organoid cells, but levels of TUBA-, MUC5A-, or ACE2-positive cells do not predict infection rate. We identify surface molecule Tetraspanin 8 (TSPAN8) as novel mediator of SARS-CoV-2 infection, which is not downregulated by this specific virus. TSPAN8 levels, prior to infection, strongly correlate with infection rate and TSPAN8-blocking antibodies diminish SARS-CoV-2 infection. We propose TSPAN8 as novel functional biomarker and potential therapeutic target for COVID-19.
What problem does this paper attempt to address?